{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:27:32Z","timestamp":1786750052832,"version":"build-2736575974"},"reference-count":73,"publisher":"Georg Thieme Verlag KG","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sepsis is a life-threatening syndrome characterized by a dysregulated host response to infection resulting in organ dysfunction. While traditional paradigms have emphasized proinflammatory cytokines, such as tumor necrosis factor-\u03b1 and interleukin-1\u03b2, interferons (IFNs) are increasingly recognized as critical yet underexplored mediators of sepsis pathobiology. IFNs are central regulators of innate and adaptive immunity and have emerged as key mediators of the immune alterations observed during sepsis. Type I IFNs (IFN-\u03b1\/\u03b2), type II IFN (IFN-\u03b3), and type III IFNs exert pleiotropic effects on immune activation, pathogen clearance, endothelial function, immunometabolism, and tissue injury. While early IFN responses support antimicrobial defense, sustained or dysregulated signaling contributes to hyperinflammation, endothelial dysfunction, immune exhaustion, coagulopathy, and multiorgan failure. Increasing evidence from experimental models and clinical studies suggests that IFN activity differs substantially among septic patients and may define biologically distinct immune endotypes. IFN-stimulated gene signatures and IFN-related biomarkers therefore represent promising tools for patient stratification and precision immunotherapy. This review summarizes the biology of IFNs relevant to sepsis, their role across different disease phases, their contribution to organ dysfunction, and emerging therapeutic strategies targeting IFN pathways. Current evidence supports a shift toward biomarker-guided and phase-specific immunomodulation aimed at restoring immune homeostasis while minimizing harmful inflammation.<\/jats:p>","DOI":"10.1055\/a-2930-7367","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:10:27Z","timestamp":1786749027000},"source":"Crossref","is-referenced-by-count":0,"title":["The Uncovered Role of Interferons in Sepsis: From Pathogenesis to Precision Immunotherapy"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9242-6505","authenticated-orcid":false,"given":"Caroline","family":"Neumann","sequence":"additional","affiliation":[{"name":"Jena University Hospital, Germany","place":["Jena"],"department":["Department of Anesthesiology and Intensive Care Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Poulain","sequence":"additional","affiliation":[{"name":"Center for Research in Transplantation and Translational Immunology, Pays de la Loire, France","place":["Nantes"],"department":["Nantes Universit\u00e9, INSERM, CHU Nantes"]},{"name":"Service d\u2019Anesthesie R\u00e9animation, Pays de la Loire, France","place":["Nantes"],"department":["Nantes Universit\u00e9, INSERM, CHU Nantes"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Roquilly","sequence":"additional","affiliation":[{"name":"Center for Research in Transplantation and Translational Immunology, Pays de la Loire, France","place":["Nantes"],"department":["Nantes Universit\u00e9, INSERM, CHU Nantes"]},{"name":"Service d\u2019Anesthesie R\u00e9animation, Pays de la Loire, France","place":["Nantes"],"department":["Nantes Universit\u00e9, INSERM, CHU Nantes"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bauer","sequence":"additional","affiliation":[{"name":"Jena University Hospital, Germany","place":["Jena"],"department":["Department of Anesthesiology and Intensive Care Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"M Singer","year":"2016","journal-title":"JAMA"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S1473-3099(13)70001-X","article-title":"Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach","volume":"13","author":"R S Hotchkiss","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"L B Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"L C Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"F McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"6693","key":"ref6","doi-asserted-by":"crossref","first-page":"eadl2016","DOI":"10.1126\/science.adl2016","article-title":"Interferon-\u03b3 and infectious diseases: lessons and prospects","volume":"384","author":"J L Casanova","year":"2024","journal-title":"Science"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4049\/jimmunol.2100707","article-title":"Beyond good and evil: molecular mechanisms of type I and III IFN functions","volume":"208","author":"J W Dowling","year":"2022","journal-title":"J Immunol"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.immuni.2021.10.012","article-title":"The immunology of sepsis","volume":"54","author":"T van der Poll","year":"2021","journal-title":"Immunity"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"16045","DOI":"10.1038\/nrdp.2016.45","article-title":"Sepsis and septic shock","volume":"2","author":"R S Hotchkiss","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"09","key":"ref10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jama.2025.24175","article-title":"Precision immunotherapy to improve sepsis outcomes: the ImmunoSep randomized clinical trial","volume":"335","author":"E J Giamarellos-Bourboulis","year":"2026","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"119014","DOI":"10.1016\/j.biopha.2026.119014","article-title":"Integrated transcriptomic and proteomic profiling identifies an interferon-dependent inflammatory endotype in sepsis","volume":"195","author":"A Fratea","year":"2026","journal-title":"Biomed Pharmacother"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13613-025-01534-z","article-title":"IFN\u03b3 in human sepsis: a scoping review","volume":"15","author":"D Thomas-R\u00fcddel","year":"2025","journal-title":"Ann Intensive Care"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.immuni.2018.12.027","article-title":"plasmacytoid dendritic cells: development, regulation, and function","volume":"50","author":"B Reizis","year":"2019","journal-title":"Immunity"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"K Schroder","year":"2004","journal-title":"J Leukoc Biol"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"H M Lazear","year":"2019","journal-title":"Immunity"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"e20190295","DOI":"10.1084\/jem.20190295","article-title":"Type III interferons: balancing tissue tolerance and resistance to pathogen invasion","volume":"217","author":"A Broggi","year":"2020","journal-title":"J Exp Med"},{"issue":"03","key":"ref17","first-page":"101678","article-title":"Macrophage activation-like syndrome in critically ill patients with sepsis: high risk patients with high mortality","volume":"45","author":"F S Schuster","year":"2026","journal-title":"Anaesth Crit Care Pain Med"},{"issue":"07","key":"ref18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2017.36","article-title":"The immunopathology of sepsis and potential therapeutic targets","volume":"17","author":"T van der Poll","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"08","key":"ref19","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.4049\/jimmunol.177.8.5623","article-title":"Type I IFN modulates host defense and late hyperinflammation in septic peritonitis","volume":"177","author":"H Weighardt","year":"2006","journal-title":"J Immunol"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hep4.1608","article-title":"Interferon type I regulates inflammasome activation and high mobility group box 1 translocation in hepatocytes during Ehrlichia-induced acute liver injury","volume":"5","author":"M Kader","year":"2020","journal-title":"Hepatol Commun"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"105414","DOI":"10.1016\/j.ebiom.2024.105414","article-title":"Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality","volume":"109","author":"E J Giamarellos-Bourboulis","year":"2024","journal-title":"EBioMedicine"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1144229","DOI":"10.3389\/fimmu.2023.1144229","article-title":"Endothelial dysfunction and immunothrombosis in sepsis","volume":"14","author":"E Maneta","year":"2023","journal-title":"Front Immunol"},{"issue":"23","key":"ref23","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2011.1829","article-title":"Immunosuppression in patients who die of sepsis and multiple organ failure","volume":"306","author":"J S Boomer","year":"2011","journal-title":"JAMA"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/emboj.2011.380","article-title":"Expression of type I interferon by splenic macrophages suppresses adaptive immunity during sepsis","volume":"31","author":"T Schwandt","year":"2012","journal-title":"EMBO J"},{"issue":"08","key":"ref25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"E J Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"e175785","DOI":"10.1172\/jci.insight.175785","article-title":"Adverse outcomes and an immunosuppressed endotype in septic patients with reduced IFN-\u03b3 ELISpot","volume":"9","author":"E L Barrios","year":"2024","journal-title":"JCI Insight"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"16136","DOI":"10.1038\/s41598-020-73014-2","article-title":"Deciphering heterogeneity of septic shock patients using immune functional assays: a proof of concept study","volume":"10","author":"C Albert Vega","year":"2020","journal-title":"Sci Rep"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nm0697-678","article-title":"Monocyte deactivation in septic patients: restoration by IFN-gamma treatment","volume":"3","author":"W D D\u00f6cke","year":"1997","journal-title":"Nat Med"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nri3547","article-title":"Age-dependent dysregulation of innate immunity","volume":"13","author":"A C Shaw","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41590-025-02136-4","article-title":"Systemic inflammation impairs myelopoiesis and interferon type I responses in humans","volume":"26","author":"F Keramati","year":"2025","journal-title":"Nat Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"103776","DOI":"10.1016\/j.ebiom.2021.103776","article-title":"Predicting sepsis severity at first clinical presentation: the role of endotypes and mechanistic signatures","volume":"75","author":"A Baghela","year":"2022","journal-title":"EBioMedicine"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(23)00330-2","article-title":"Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine","volume":"12","author":"S Cajander","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"09","key":"ref33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nri.2016.70","article-title":"A guide to immunometabolism for immunologists","volume":"16","author":"L A O'Neill","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ni.3398","article-title":"Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis","volume":"17","author":"S C Cheng","year":"2016","journal-title":"Nat Immunol"},{"issue":"10","key":"ref35","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s00134-024-07586-2","article-title":"Understanding, assessing and treating immune, endothelial and haemostasis dysfunctions in bacterial sepsis","volume":"50","author":"M Girardis","year":"2024","journal-title":"Intensive Care Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2016.11.007","article-title":"Coagulation and sepsis","volume":"149","author":"M Levi","year":"2017","journal-title":"Thromb Res"},{"issue":"13","key":"ref37","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.3390\/ijms26136114","article-title":"Immunothrombosis in sepsis: cellular crosstalk, molecular triggers, and therapeutic opportunities-a review","volume":"26","author":"A Aklilu","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"M A Matthay","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"C153","DOI":"10.1152\/ajpcell.00120.2007","article-title":"IFN-alpha induces barrier destabilization and apoptosis in renal proximal tubular epithelium","volume":"294","author":"J Lechner","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.kint.2022.02.031","article-title":"Type I interferon-related kidney disorders","volume":"101","author":"L Lodi","year":"2022","journal-title":"Kidney Int"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"114310","DOI":"10.1016\/j.celrep.2024.114310","article-title":"Interferon-\u03b3 induces combined pyroptotic angiopathy and APOL1 expression in human kidney disease","volume":"43","author":"B A Juliar","year":"2024","journal-title":"Cell Rep"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1740461","DOI":"10.3389\/fimmu.2026.1740461","article-title":"Regulated cell death in sepsis-associated liver injury: molecular mechanisms and therapeutic implications","volume":"17","author":"K Zou","year":"2026","journal-title":"Front Immunol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1504223","DOI":"10.3389\/fcimb.2025.1504223","article-title":"Mechanisms of sepsis-induced acute liver injury: a comprehensive review","volume":"15","author":"Y Guo","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"109276","DOI":"10.1016\/j.intimp.2022.109276","article-title":"Blocking cGAS\/STING signaling protects against sepsis-associated acute liver injury","volume":"113","author":"J Li","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"05","key":"ref45","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41590-025-02143-5","article-title":"Interferon-\u03b2 treatment restores myeloid function and reverses immunosuppression in sepsis","volume":"26","year":"2025","journal-title":"Nat Immunol"},{"issue":"04","key":"ref46","first-page":"5350","article-title":"Identification of risk factors for sepsis-associated mortality by gene expression profiling analysis","volume":"17","author":"Y Qi","year":"2018","journal-title":"Mol Med Rep"},{"issue":"11","key":"ref47","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41584-021-00694-z","article-title":"Targeting interferon-\u03b3 in hyperinflammation: opportunities and challenges","volume":"17","author":"F De Benedetti","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","article-title":"Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies","volume":"66","author":"G S Schulert","year":"2015","journal-title":"Annu Rev Med"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1186\/s12879-019-4526-x","article-title":"Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series","volume":"19","author":"D Payen","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00134-023-07065-0","article-title":"Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial","volume":"49","author":"A Roquilly","year":"2023","journal-title":"Intensive Care Med"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13054-026-05946-6","article-title":"Identification of a robust metabolic signature associated with hospital-acquired pneumonia and response to interferon-gamma treatment in critically ill patients","volume":"30","author":"M Petrier","year":"2026","journal-title":"Crit Care"},{"issue":"09","key":"ref52","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1164\/rccm.201204-0645OC","article-title":"Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study","volume":"186","author":"J Leentjens","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"ref53","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"F J Barrat","year":"2019","journal-title":"Nat Immunol"},{"issue":"06","key":"ref54","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard-2022-223628","article-title":"2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice","volume":"82","author":"J Rodr\u00edguez-Carrio","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2665-9913(21)00254-X","article-title":"The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease","volume":"4","author":"F AH Cooles","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00134-025-08218-z","article-title":"Temporal robustness of biomarker-based classification algorithms for sepsis","volume":"52","author":"E Rademaker","year":"2026","journal-title":"Intensive Care Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1498974","DOI":"10.3389\/fimmu.2024.1498974","article-title":"Time-dependent variation in immunoparalysis biomarkers among patients with sepsis and critical illness","volume":"15","author":"A Samuelsen","year":"2024","journal-title":"Front Immunol"},{"issue":"12","key":"ref58","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S1473-3099(19)30567-5","article-title":"Current gaps in sepsis immunology: new opportunities for translational research","volume":"19","author":"I Rubio","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13054-024-05032-9","article-title":"Enhancing sepsis biomarker development: key considerations from public and private perspectives","volume":"28","author":"J F Llitjos","year":"2024","journal-title":"Crit Care"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/infdis\/jit600","article-title":"Pharmacological inhibition of type I interferon signaling protects mice against lethal sepsis","volume":"209","author":"L Dejager","year":"2014","journal-title":"J Infect Dis"},{"issue":"04","key":"ref61","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"G R Stark","year":"2012","journal-title":"Immunity"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-2334-14-166","article-title":"Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series","volume":"14","author":"C E Delsing","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"12","key":"ref63","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1128\/AAC.01533-15","article-title":"Treatment of experimental candida sepsis with a Janus kinase inhibitor controls inflammation and prolongs survival","volume":"59","author":"P Tsirigotis","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","author":"RECOVERY Collaborative Group","year":"2022","journal-title":"Lancet"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"177770","DOI":"10.1016\/j.ejphar.2025.177770","article-title":"JAK1\/JAK2 inhibitor baricitinib ameliorates sepsis-induced acute kidney injury in rats","volume":"1002","author":"M \u00c7ak\u0131r","year":"2025","journal-title":"Eur J Pharmacol"},{"issue":"03","key":"ref66","first-page":"859","article-title":"Inhibition of Janus kinase 2 and signal transduction and activator of transcription 3 protect against cecal ligation and puncture-induced multiple organ damage and mortality","volume":"66","author":"L Hui","year":"2009","journal-title":"J Trauma"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: what do they all do?","volume":"6","author":"J W Schoggins","year":"2019","journal-title":"Annu Rev Virol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s10495-025-02099-9","article-title":"Pharmacological inhibition of STING-mediated GPX4 autophagic degradation by 4-octyl itaconate ameliorates sepsis-induced acute kidney injury","volume":"30","author":"Y Wang","year":"2025","journal-title":"Apoptosis"},{"issue":"09","key":"ref69","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s13238-018-0511-1","article-title":"Identification of new type I interferon-stimulated genes and investigation of their involvement in IFN-\u03b2 activation","volume":"9","author":"X Zhang","year":"2018","journal-title":"Protein Cell"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2017.03.013","article-title":"Adjuvant interferon-gamma immunotherapy in a patient with progressive cerebral Nocardia abscesses","volume":"59","author":"J Leentjens","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"11","key":"ref71","doi-asserted-by":"crossref","first-page":"100817","DOI":"10.1016\/j.xcrm.2022.100817","article-title":"Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial","volume":"3","author":"K Leventogiannis","year":"2022","journal-title":"Cell Rep Med"},{"issue":"03","key":"ref72","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.ygeno.2021.01.026","article-title":"Single-cell RNA sequencing reveals the sustained immune cell dysfunction in the pathogenesis of sepsis secondary to bacterial pneumonia","volume":"113","author":"T Wang","year":"2021","journal-title":"Genomics"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1616794","DOI":"10.3389\/fimmu.2025.1616794","article-title":"Single-cell multi-omics-based immune temporal network resolution in sepsis: unravelling molecular mechanisms and precise therapeutic targets","volume":"16","author":"H Liu","year":"2025","journal-title":"Front Immunol"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2930-7367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:10:35Z","timestamp":1786749035000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2930-7367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":73,"URL":"https:\/\/doi.org\/10.1055\/a-2930-7367","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}